Information Provided By:
Fly News Breaks for January 27, 2016
MDVN
Jan 27, 2016 | 06:51 EDT
Canaccord analyst John Newman downgraded Medivation to Hold on slowing Xtandi growth. The analyst believes Xtandi has gained peak uptake among oncologists and a much larger sales effort is needed to increase growth among urologists. Newman pushed out his peak $3B US Xtandi estimate to 2025 from 2020 to reflect a more gradual urologist uptake.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.